Viriom: Viriom Initiates Phase 2 Clinical Study of Elsulfavirine for Treatment of COVID-19
SAN DIEGO, April 8, 2020 /PRNewswire/ -- Viriom, Inc. today announced the initiation of a Phase 2 clinical study to evaluate the efficacy of elsulfavirine in adults with moderate manifestations of COVID-19 (novel coronavirus).
Read full article »
Viriom is a biotech company that develops and commercializes novel therapies for the treatment of life threatening infections such as HIV and HBV.
Read more